From: Overuse in cancer care: do European studies provide information useful to support policies?
 | Breast cancer | Colorectal cancer | Lung cancer | Prostate cancer | Miscellaneousa | Total |
---|---|---|---|---|---|---|
N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
Year of publication | ||||||
 ≤ 2010  (%) | 11 (29) (38) | 7 (23) (24) | 3 (38) (10) | 4 (44) (14) | 4 (44) (14) | 29 (31) (100) |
 2011–2012  (%) | 11 (29) (44) | 8 (27) (32) | 3 (38) (12) | 1 (11) (4) | 2 (22) (8) | 25 (26.5) (100) |
 2013–2014  (%) | 6 (16) (24) | 13 (43) (52) | 2 (25) (8) | 1 (11) (4) | 3 (33) (12) | 25 (26.5) (100) |
 2015–2016  (%) | 10 (26) (66.7) | 2 (7) (13.3) | 0 (0) (0) | 3 (33) (20) | 0 (0) (0) | 15 (16) (100) |
Study design | ||||||
 Cross-sectional  (%) | 21 (55.3) (49) | 8 (27) (19) | 4 (50) (9) | 4 (44) (9) | 6 (67) (14) | 43 (46) (100) |
 Cohort  (%) | 17 (44.7) (33) | 22 (73) (43) | 4 (50) (8) | 5 (56) (10) | 3 (33) (6) | 51 (54) (100) |
Data sources | ||||||
 Cancer registry  (%) | 17 (44.7) (34.7) | 18 (60) (36.7) | 6 (75) (12.2) | 7 (77.8) (14.2) | 1 (11.1) (2) | 49 (52) (100) |
 Cancer registry + administrative databases  (%) | 6 (15.8) (75) | 1 (3.3) (12.5) | 1 (12.5) (12.5) | 0 (0) (0) | 0 (0) (0) | 8 (8) (100) |
 Administrative databases alone  (%) | 8 (21) (66.7) | 1 (3.3) (8.3) | 0 (0) (0) | 1 (11.1) (8.3) | 2 (22.2) (16.7) | 12 (13) (100) |
 Other sources  (%) | 7 (18.4) (28) | 10 (33.3) (40) | 1 (12.5) (4) | 1 (11.1) (4) | 6 (66.7) (24) | 25 (27) (100) |
Type of measures | ||||||
 Generic  (%) | 17 (44.7) (3.,4) | 16 (53.4) (33.3) | 5 (62.5) (10.4) | 5 (55.5) (10.4) | 5 (55.5) (10.4) | 48 (51) (100) |
 Oriented towards underuse  (%) | 8 (21) (33.5) | 10 (33.3) (42) | 3 (37.5) (12.5) | 1 (11.1) (4) | 2 (22.2) (8) | 24 (26) (100) |
 Oriented towards overuse  (%) | 13 (34.2) (59.1) | 4 (13.3) (18.2) | 0 (0) (0) | 3 (33.3) (13.6) | 2 (22.2) (9.1) | 22 (23) (100) |
 Total  (%) | 38 (100) (40) | 30 (100) (32.5) | 8 (100) (8.5) | 9 (100) (9.5) | 9 (100) (9.5) | 94 (100) (100) |